Should I buy Amgen (AMGN) stock or is it too late?
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $450 (+3.0 %), call made on August 6, 2026, maturing on August 6, 2027 (22 d ago).
Firm-by-firm track record on Amgen
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Citigroup | 100 % | +29.3 % | 9 | $405 -7% |
| Jefferies | 85 % | +17.6 % | 13 | $350 -20% |
| Argus Research | 78 % | +15.6 % | 9 | $460 +5% |
| Piper Sandler | 74 % | +13.1 % | 19 | $457 +5% |
| Oppenheimer | 67 % | +9.1 % | 21 | $450 +3% |
| Morgan Stanley | 57 % | +4.3 % | 30 | $333 -24% |
| RBC Capital | 40 % | +3.8 % | 10 | $400 -8% |
| BMO Capital | 38 % | +3.1 % | 8 | $450 +3% |
✅ Reasons to believe
- Pays a dividend (2.7% yield), raised for 14 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- Even the most reliable firm on AMGN, Citigroup (100% hit rate, 9 scored calls), only targets $405 (call made on August 7, 2026, maturing on August 7, 2027) (-7%) in its most recent call, and $345 (call made on February 4, 2026, maturing on February 4, 2027) (-21%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 19 ratings, 11 are neutral.
- Limited upside: the median target is only -8% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on AMGN
Median target $400 (-8%) · 19 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Amgen now?
We won't decide for you. The facts: 42% of analysts rate it a buy, median target $400 (-8%), and Citigroup (most reliable on AMGN, 100%) targets $405. Weigh that against valuation (P/E ~27). This is not personalized advice.
Is it too late to invest in Amgen?
The stated upside is small: the median target ($400) sits just -8% from the price ($437) (most reliable on AMGN: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Amgen still worth investing in?
It depends on the gap between the price ($437) and its estimated value: analysts target $400 on median (-8%), with 42% buys (most reliable on AMGN: Citigroup, 100%). Cross-check with their real reliability on AMGN and the cautions above. Information, not advice.
What's the main risk in buying AMGN?
Even the most reliable firm on AMGN, Citigroup (100% hit rate, 9 scored calls), only targets $405 (call made on August 7, 2026, maturing on August 7, 2027) (-7%) in its most recent call, and $345 (call made on February 4, 2026, maturing on February 4, 2027) (-21%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full Amgen profile (consensus, analyst reliability, price target, performance).